Search

Displaying results 6621 - 6630 of 7067 in total
  1. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. … In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal

  2. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

  3. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being develop...

  4. Drug

    PAC-113

    go.drugbank.com/drugs/DB05756
    Investigational

    It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.

  5. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.

  6. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    It is a dual agent with both immunomodulatory and antiproliferative activities. … Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.

  7. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.

  8. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  9. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  10. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".